组蛋白去乙酰化酶6作为治疗心血管疾病的一个新的有前景的靶点。
Histone deacetylase 6 as a novel promising target to treat cardiovascular disease.
作者信息
Wu Ya-Xi, Li Bing-Qian, Yu Xiao-Qian, Liu Yu-Lin, Chui Rui-Hao, Sun Kai, Geng Dian-Guang, Ma Li-Ying
机构信息
State Key Laboratory of Esophageal Cancer Prevention and Treatment, Key Laboratory of Advanced Pharmaceutical Technology, Ministry of Education of China, School of Pharmaceutical Science and Institute of Pharmaceutical Science Zhengzhou University Zhengzhou Henan China.
Key Laboratory of Cardio-Cerebrovascular Drugs' China Meheco Topfond Pharmaceutical Co. Zhumadian Henan China.
出版信息
Cancer Innov. 2024 May 7;3(3):e114. doi: 10.1002/cai2.114. eCollection 2024 Jun.
Histone deacetylase 6 (HDAC6) belongs to a class of epigenetic targets that have been found to be a key protein in the association between tumors and cardiovascular disease. Recent studies have focused on the crucial role of HDAC6 in regulating cardiovascular diseases such as atherosclerosis, myocardial infarction, myocardial hypertrophy, myocardial fibrosis, hypertension, pulmonary hypertension, and arrhythmia. Here, we review the association between HDAC6 and cardiovascular disease, the research progress of HDAC6 inhibitors in the treatment of cardiovascular disease, and discuss the feasibility of combining HDAC6 inhibitors with other therapeutic agents to treat cardiovascular disease.
组蛋白去乙酰化酶6（HDAC6）属于一类表观遗传靶点，已被发现是肿瘤与心血管疾病关联中的关键蛋白。最近的研究聚焦于HDAC6在调节心血管疾病如动脉粥样硬化、心肌梗死、心肌肥大、心肌纤维化、高血压、肺动脉高压和心律失常中的关键作用。在此，我们综述HDAC6与心血管疾病之间的关联、HDAC6抑制剂在治疗心血管疾病方面的研究进展，并讨论将HDAC6抑制剂与其他治疗药物联合用于治疗心血管疾病的可行性。
Zotero 插件